biontech

News

Pfizer’s Vaccine Approval Fuels Rally on Wall Street

By Bhushan Akolkar Aug 24, 2021

Pfizer becomes the first drugmaker to receive full-fledged approval from the US FDA. The approval will help people to gain confidence and especially businesses to drive growth ahead.

Market News, News

Vaccine Stocks Soar in Wake of Renewed Coronavirus Fears

By Tolu Ajiboye Aug 10, 2021

Stocks of major vaccine makers rose on Monday amid renewed outbreak of COVID-19. Moderna CEO adds that vaccine makers have a huge opportunity for growth.

Market News, News

Pfizer and Moderna COVID-19 Vaccines Proves Effective in Real-World Use after First Shot

By Godfrey Benjamin Mar 30, 2021

The potential efficacy in the approved Pfizer-BioNTech and Moderna vaccines is spurring a delay in second dose administration by some nations, especially those with limited supplies of the jabs.

Market News, News

SAN Stock Up 0.52%, Sanofi to Begin Human Trials of Second COVID-19 Vaccine

By Tolu Ajiboye Mar 12, 2021

Sanofi will begin testing its second COVID-19 vaccine on 415 people today. First results are expected sometime between July and September 2021.

News

AZN Stock Jumped 3%, WHO Approves AstraZeneca Coronavirus Vaccine for Emergency Use

By Steve Muchoki Feb 16, 2021

Notably, the World Health Organization has approved two different versions of the AstraZeneca vaccine that were found out to be approximately 63% effective. 

Market News, News

When will Coronavirus Pandemic End with Today’s Vaccine Rates?

By Oluwapelumi Adejumo Feb 5, 2021

According to a recent poll carried out by IBD/TIPP, more Americans are now willing to get vaccinated immediately when it becomes available to them.

Market News, News

PFE Stock Down 2%, Pfizer Reports Profitable Q4, Works on Adapting Vaccine to New Strains

By Godfrey Benjamin Feb 3, 2021

Pfizer raised its earnings guidance for the 2021 fiscal year noting that its revenues will range between $59.4 billion and $61.4 billion, with vaccine sales taking a prominent role in the achievement.

Market News, News

Moderna (MRNA) Stock Up 1% after Falling 9% in Reaction to Downgrade by BoA

By Ibukun Ogundare Feb 2, 2021

In 2021, it is expected that Moderna will to generate $11 billion in revenue from its vaccine.

Market News, News

MRK Stock Down 1% in Pre-market, Merck Halts Its Covid-19 Vaccine Development

By Steve Muchoki Jan 25, 2021

Merck has a reported market valuation of approximately $204.88 billion with 2.53 billion outstanding shares. The company’s leadership has opted to commit its resources towards developing coronavirus therapy drugs.

Market News, News

Vaccine Rollout Influences Investment Decisions as Pfizer and BioNTech Agree to Supply COVAX Program Co-led by WHO

By Ibukun Ogundare Jan 22, 2021

Pfizer and BioNTech will supply a COVAX program to accelerate vaccine distribution in lower-income countries.

Market News, News

Pfizer-BioNTech Vaccine Is Efficient Against UK COVID Variant, PFE Stock Slightly Up

By Godfrey Benjamin Jan 20, 2021

The vaccine from the duo of Pfizer-BioNTech as well as Moderna is expected to fetch the firms as much as $15 billion in sales by the year 2023.

Market News, News

AZN Stock Jumps 3% as UK Begins Rollout of Oxford-AstraZeneca COVID-19 Vaccine

By Godfrey Benjamin Jan 4, 2021

The AstraZeneca (AZN) shares are up today with investors bearing the sentiment that the stock will witness an improved performance thanks to the obvious advantages the Oxford-AZN vaccine has over its rivals.